Naloxegol oxalate is a Small Molecule owned by AstraZeneca, and is involved in 27 clinical trials, which were completed.

Naloxegol is a peripherally-acting mu opioid antagonist. It antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Opioids play an important role in chronic pain relief. They work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from OIC(opioid-induced constipation). Naloxegol acts on mu-receptors in the gastrointestinal tract elliciting antagonist activity, such as to provide relief from opioid-induced constipation.

The revenue for Naloxegol oxalate is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Naloxegol oxalate NPV Report.

Naloxegol oxalate is currently owned by AstraZeneca. RedHill Biopharma and Kyowa Kirin are the other companies associated in development or marketing of Naloxegol oxalate.

Naloxegol oxalate Overview

Naloxegol oxalate (Movantik, Moventig, PEG-Naloxol) is an anti-constipation agent. It is formulated as pegylated film coated tablets for oral route of administration. Naloxegol is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

RedHill Biopharma Overview

RedHill Biopharma (Redhill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutinomeprazole; naloxegol; and rifamycin. It is investigating its pipeline candidates for the treatment of Crohn’s disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. Redhill is headquartered in Tel Aviv, Israel.

The company reported revenues of (US Dollars) US$85.8 million for the fiscal year ended December 2021 (FY2021), an increase of 33.2% over FY2020. The operating loss of the company was US$81.1 million in FY2021, compared to an operating loss of US$63.7 million in FY2020. The net loss of the company was US$97.7 million in FY2021, compared to a net loss of US$76.2 million in FY2020. The company reported revenues of US$17.6 million for the third quarter ended September 2022, a decrease of 4.3% over the previous quarter.

Quick View – Naloxegol oxalate

Report Segments
  • Innovator (NME)
Drug Name
  • Naloxegol oxalate
Administration Pathway
  • Oral
Therapeutic Areas
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.